Figure 7.

VPA confers TGF-β-induced sorafenib resistance. (A) Cells were independently treated for 7 h with agents, or (B) treated with a combination of sorafenib and agents, or (C) treated with combination treatment with or without TGF-β pretreatment, and the ratios of dead cells were analyzed using trypan blue. (D) Cells were pretreated with TGF-β, and thereafter treated with sorafenib plus VPA. Cell proliferation was assessed by WST assay. White column, sorafenib-free control cells. Experiments were performed in triplicate, and data represent the means ± SD of triplicate experiments (*P<0.05).